MGI PHARMA SALAGEN sNDA FOR SJOGREN's SYMPTOMS TO BE FILED BY EARLY 1997; FDA AGREES TO DISSEMINATION OF ABSTRACT ON EARLY USE OF SALAGEN WITH RADIATION
Executive Summary
MGI Pharma is planning to submit a supplemental NDA for Salagen (pilocarpine tablets) for the treatment of dry mouth and dry eyes associated with Sjogren's syndrome "before the end of 1996 or very early in 1997," the company said.